Botox (onabotulinumtoxinA, AbbVie/Allergan Aesthetics) and Jeuveau (prabotulinumtoxinA, Evolus) are both FDA-approved neuromodulators with equivalent mechanism of action—they block acetylcholine release at the neuromuscular junction—but differ in manufacturing process, market position, rebate structure, and patient acquisition cost. The choice hinges on your practice economics, payer mix, and competitive positioning.
Injectables
Botox vs Jeuveau: Which Neuromodulator to Stock and Offer
Botox dominates market share and rebate programs, but Jeuveau offers competitive unit pricing and differentiation—here's how to choose for your practice.
